RNA 疗法的全球市场：增长机会

核酸疗法的科学进步正在对全球生物製药行业产生重大影响。 RNA（核糖核酸）治疗市场有望取得重大临床进展，因为它针对“无法治愈”的途径。对技术优势的日益增长的需求以及建立临床上优越的 RNA 疗法组合以提高竞争力的需求预计将促进 RNA 疗法行业利益相关者之间的战略伙伴关係。

本报告研究和分析全球 RNA 治疗市场，并提供有关战略必要因素、驱动因素、限制因素、主要趋势、盈利预测、竞争环境、增长机会等方面的信息。

目录

战略要素

• 为什么增长变得越来越困难？
• 战略要素 8 (TM)
• 三大战略要素对 RNA 治疗行业的影响
• 增长机会推动增长管道引擎 (TM)

增长机会分析

• 分析范围
• 细分
• 调查方法
• 重点
• 成长指标
• 增长动力
• 增长限制
• 主要趋势
• 主要疾病的适应症
• 2021 年管道快照
• 价值链关键利益相关者
• 主要利益相关者造成混乱
• 製造商的区域快照
• 满足 SM 製造和供应需求的策略
• 利益相关者在供应链中不断演变的角色
• RNA 疗法生物製造的总体变化
• 分销和供应框架
• 主要合作主题
• 着名的合作伙伴关係
• 着名的 mRNA 製造合作伙伴：按地区-欧洲
• 着名的 mRNA 製造合作伙伴：按地区-美国
• 预测的先决条件
• 收入预测
• 收入预测分析
• 收入预测：按产品类型
• 正在开发的主要模式
• 竞争环境
• 市场份额分析

增长机会宇宙

• 增长机会1-增加对免疫肿瘤学的关注以满足对肿瘤特异性治疗的需求
• 增长机会 2-优化 LNP 递送以解决 RNA 治疗稳定性问题
• 增长机会 3-扩大 CDMO 能力以支持生物製药公司
• 图表列表
• 免责声明

Future Growth Potential Driven by Co-Development Programs and Robust Clinical Trials for Diverse Disease Areas

Scientific advancements in nucleic acid-based therapies have significantly impacted the global biopharmaceutical industry. The ribonucleic acid (RNA) therapeutics market is expected to witness remarkable clinical progress as therapies target "undruggable" pathways. Technologically advanced platforms are integrated into RNA therapeutics bioprocessing to overcome stability issues. Technological advantages, coupled with the growing need to build clinically superior portfolios in RNA therapeutics for a competitive edge, are anticipated to drive strategic partnerships among stakeholders in the RNA therapeutics industry.

Spurred by the COVID-19 pandemic, biopharmaceutical companies are likely to prioritize microRNA, small interfering RNA, and antisense oligonucleotides as promising therapeutic modalities during the forecast period. Midsize and large companies have ramped up the production of starting materials and the final formulation of RNA therapeutics, which is likely to propel stakeholders to seek synergistic partnerships. In the industry's transition to personalized therapeutics, RNA developers are capitalizing on the high precision of RNA to treat untapped chronic disease areas such as cystic fibrosis, solid tumors, and spinal muscular atrophy. They engage in co-development programs to improve the stability profile of RNA therapeutics by optimizing drug delivery carriers, such as lipid nanoparticles.

Scaling up the production of starting materials, including plasmid DNA, oligonucleotides, and delivery materials, to ensure continuous manufacturing is anticipated to reduce the operational timeframe of RNA therapeutics production. Technology transfer and the outsourcing of crucial operations to contract development and manufacturing organizations (CDMO) catalyze the development of cost-effective and efficient models for RNA therapeutics.

This Frost & Sullivan research service provides an overview of the global RNA therapeutics industry from 2021 to 2027, including emerging trends, growth drivers, and growth opportunities.

The research service highlights the following:

• RNA therapeutics market size, including key segments from 2022 to 2027

• Advancements in bioprocessing, modalities, and technologies that are shaping the market

• Current and future R&D, investment outlook, and trends

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the RNA Therapeutics Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation
• Research Methodology
• Key Takeaways
• Growth Metrics
• Growth Drivers
• Growth Restraints
• Key Trends
• Key Disease Indications
• Pipeline Snapshot for 2021
• Value Chain-Key Stakeholders
• Value Chain-Key Stakeholders (continued)
• Notable Stakeholders Driving Disruption
• Regional Snapshot of Manufacturers
• Strategies to Meet SM Manufacturing and Supply Needs
• Evolving Role of Stakeholders in the Supply Chain
• Evolving Role of Stakeholders in the Supply Chain (continued)
• Holistic Changes in RNA Therapeutics Biomanufacturing
• Distribution and Supply Framework
• Key Partnership Themes
• Notable Partnerships
• Notable Partnerships (continued)
• Notable mRNA Manufacturing Partnerships by Region-Europe
• Notable mRNA Manufacturing Partnerships by Region-US
• Forecast Assumptions
• Revenue Forecast
• Revenue Forecast Analysis
• Percent Revenue Forecast by Product Type
• Key Modalities Under Development
• Competitive Environment
• Market Share Analysis

Growth Opportunity Universe

• Growth Opportunity 1-Increase Focus on Immuno-oncology to Meet the Demand for Tumor-specific Targeted Therapeutics
• Growth Opportunity 1-Increase Focus on Immuno-oncology to Meet the Demand for Tumor-specific Targeted Therapeutics (continued)
• Growth Opportunity 2-Optimize LNP Delivery to Address the Stability Issues of RNA Therapeutics
• Growth Opportunity 2-Optimize LNP Delivery to Address the Stability Issues of RNA Therapeutics (continued)
• Growth Opportunity 3-Expand CDMO Capabilities to Support Biopharmaceutical Companies
• Growth Opportunity 3-Expand CDMO Capabilities to Support Biopharmaceutical Companies (continued)
• Growth Opportunity 3-Expand CDMO Capabilities to Support Biopharmaceutical Companies (continued)
• List of Exhibits
• Legal Disclaimer